Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.46 |
| ▸ | TACR1 | P25103 | 2/20 | 0.43 |
| ▸ | ICMT | O60725 | 5/20 | 0.40 |
| ▸ | CETP | P11597 | 1/20 | 0.40 |
| ▸ | POLQ | O75417 | 1/20 | 0.40 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | GPR52 | Q9Y2T5 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.39 |
| ▸ | GPR3 | P46089 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9892668 | 0.86 | POLQ (0.45) | PTGDR2ICMTCETPPOLQGPR3 | |
| SCHEMBL2394221 | 0.85 | NPSR1 (0.44) | PTGDR2TACR1ICMTMRGPRX4 | |
| SCHEMBL2395095 | 0.83 | PTGDR2 (0.40) | PTGDR2ICMTPOLQ | |
| SCHEMBL9890747 | 0.82 | ALDH1A1 (0.44) | PTGDR2TACR1ICMT | |
| SCHEMBL8566067 | 0.81 | RXRA (0.54) | PTGDR2ICMTPOLQ | |
| SCHEMBL9890710 | 0.80 | FFAR1 (0.43) | ICMT | |
| SCHEMBL9890734 | 0.80 | FFAR1 (0.49) | PTGDR2TACR1ICMT | |
| SCHEMBL2391627 | 0.79 | RORB (0.51) | ICMT | |
| SCHEMBL9890739 | 0.78 | ICMT (0.52) | TACR1ICMT | |
| SCHEMBL27748319 | 0.78 | JAK2 (0.46) | PTGDR2CETPPOLQMRGPRX4GPR52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2012-06-07 | — | — | US | disclosed |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120142771-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | PTGDR2 1062/4885TACR1 2276/4885ICMT 2894/4885 |
| US-20110224304-A1 | BIPHENYLACETAMIDE DERIVATIVE | HRH3, KCNH3, BRPF3 | PTGDR2 1062/4885TACR1 2276/4885ICMT 2894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.